Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Reliability and Validity01:29

Reliability and Validity

13.8K
Reliability and validity are two important considerations that must be made with any type of data collection. Reliability refers to the ability to consistently produce a given result. In the context of psychological research, this would mean that any instruments or tools used to collect data do so in consistent, reproducible ways.
13.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

665
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
665
Relative Risk01:12

Relative Risk

2.1K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.1K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Data Validation01:03

Data Validation

6.5K
Data validation is an essential part of a comprehensive assessment. Validation is confirming or verifying and opening the door to gathering more assessment data as it clarifies vague or unclear data. The process of checking and verifying the collected information is called data validation. The primary purpose of data validation is to ensure data is as free from error, bias, and misinterpretation as possible.
Nursing assessment guides are generally based on holistic models rather than medical...
6.5K
Data Validation01:15

Data Validation

1.2K
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking success in modern urology.

BJU international·2026
Same author

<i>In vivo</i> proton magnetic resonance spectroscopy of the human kidney and kidney lesions: new protocol.

Translational andrology and urology·2026
Same author

Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

The Lancet. Oncology·2026
Same author

Reply to Varma et al. regarding building consensus in medicine: issues and potential solutions.

Virchows Archiv : an international journal of pathology·2026
Same author

Integrated Biodevice for Parallel Magnetic Isolation and Bioelectrocatalytic Detection of Circulating DNA and RNA Biomarkers in Non-Small Cell Lung Cancer Liquid Biopsy.

ACS sensors·2026
Same author

Spatially Profiling Trace Cytokine Signatures From Microscopically Derived Skin Samples to Probe Skin Disease Inflammation.

Small methods·2026

Related Experiment Video

Updated: Jan 28, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

735

Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical

Kevin M Koo1,2,3, Grant Phillips2, Sriganesh Srihari4

  • 1The University of Queensland Centre for Clinical Research (UQCCR), Brisbane, QLD, Australia.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|January 27, 2026
PubMed
Summary
This summary is machine-generated.

A new biosensor, AVATAR, offers rapid, accurate, decentralized prostate cancer (PCa) molecular profiling from urine liquid biopsies. This technology improves risk stratification and aids precision cancer management, overcoming limitations of centralized testing.

Keywords:
biomarkersbiosensorclinical validationliquid biopsyprostate cancer

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.3K
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.6K

Related Experiment Videos

Last Updated: Jan 28, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

735
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.3K
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.6K

Area of Science:

  • Biomedical Engineering
  • Molecular Diagnostics
  • Oncology

Background:

  • Liquid biopsies are vital for targeted cancer treatment, but current methods face limitations like high costs and long turnaround times.
  • Decentralized testing is needed to overcome logistical hurdles and improve patient accessibility for molecular profiling.
  • Rigorous clinical validation of emerging liquid biopsy technologies is crucial for their translation into clinical practice.

Purpose of the Study:

  • To report advancements in liquid biopsy biosensor technology for rapid, accurate, and decentralized molecular profiling of prostate cancer (PCa).
  • To evaluate the performance of the AVATAR (Accelerated non-inVasive bioAnalyte testing And Reporting) biosensor system for PCa risk stratification using urinary circulating RNA biomarkers.
  • To establish a framework for the clinical translation of biosensor technology for precision cancer management.

Main Methods:

  • Development of the AVATAR biosensor platform integrating isothermal assay chemistry and wireless mobile capabilities on a portable electrochemical readout.
  • Utilized a custom mobile app for operational control and result display following liquid biopsy specimen collection.
  • Conducted independent training (n=124) and validation (n=114) studies using PCa clinical urinary specimens and a follow-up study (n=39) correlating with tissue transcriptomic sequencing.

Main Results:

  • The AVATAR biosensor achieved superior PCa risk stratification compared to current clinical testing, with AUC values of 0.88 and 0.86 in training and validation cohorts, respectively.
  • Assay time was significantly reduced to within 55 minutes for molecular profiling.
  • Demonstrated strong molecular biomarker correlation between urinary liquid biopsies and matched tissue specimens, supporting AVATAR's utility as a surrogate for invasive sampling.

Conclusions:

  • The AVATAR biosensor technology enables rapid, accurate, and decentralized molecular profiling of PCa using urinary liquid biopsies.
  • This advancement facilitates improved PCa risk stratification and has the potential to augment clinical precision cancer management planning.
  • The developed framework supports the clinical translation of biosensor technologies for accessible and efficient cancer diagnostics.